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AbstrACt
Introduction Postoperative morbidity and mortality in older 
patients with comorbidities undergoing gastrointestinal 
surgery are a major burden on healthcare systems. Infections 
after surgery are common in such patients, prolonging 
hospitalisation and reducing postoperative short-term and 
long-term survival. Optimal management of perioperative 
intravenous fluids and inotropic drugs may reduce infection 
rates and improve outcomes from surgery. Previous small 
trials of cardiac-output-guided haemodynamic therapy 
algorithms suggested a modest reduction in postoperative 
morbidity. A large definitive trial is needed to confirm or refute 
this and inform widespread clinical practice.
Methods The Optimisation of Perioperative Cardiovascular 
Management to Improve Surgical Outcome II (OPTIMISE 
II) trial is a multicentre, international, parallel group, open, 
randomised controlled trial. 2502 high-risk patients 
undergoing major elective gastrointestinal surgery will 
be randomly allocated in a 1:1 ratio using minimisation 
to minimally invasive cardiac output monitoring to guide 
protocolised administration of intravenous fluid combined with 
low-dose inotrope infusion, or usual care. The trial intervention 
will be carried out during and for 4 hours after surgery. The 
primary outcome is postoperative infection of Clavien-Dindo 
grade II or higher within 30 days of randomisation. Participants 
and those delivering the intervention will not be blinded to 
treatment allocation; however, outcome assessors will be 
blinded when feasible. Participant recruitment started in 
January 2017 and is scheduled to last 3 years, within 50 
hospitals worldwide.
Ethics/dissemination The OPTIMISE II trial has been 
approved by the UK National Research Ethics Service and 
has been approved by responsible ethics committees in all 
participating countries. The findings will be disseminated 
through publication in a widely accessible peer-reviewed 
scientific journal.
trial registration number ISRCTN39653756.
strengths and limitations of this study
 ► This will be the largest contemporary randomised 
trial examining the effectiveness and safety of 
perioperative cardiac output-guided haemodynamic 
therapy in patients undergoing major elective gas-
trointestinal surgery.
 ► The primary outcome is postoperative infection, 
which is a major healthcare burden of clear impor-
tance to patients.
 ► The multicentre, international design and broad in-
clusion criteria support the external validity of the 
trial.
 ► Although the clinical teams delivering the trial inter-
ventions will not be blinded, research staff assess-
ing clinical outcomes will not be aware of treatment 
group allocation.
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IntroduCtIon 
Surgery is an increasingly popular treatment, with an 
estimated 310 million operations carried out each year 
worldwide.1 2 Although serious failures in surgical or 
anaesthetic technique are rare, complications during 
recovery from surgery are much more common. Older 
patients with comorbidities undergoing major gastroin-
testinal surgery are at particularly high risk of postop-
erative morbidity.3–5 Hospital-acquired infections occur 
frequently in this group because of the physiological 
and inflammatory changes caused by the tissue injury of 
major surgery, combined with bacterial microexposure 
due to surgical manipulation of the gut. Meanwhile, the 
consequences of infection are more serious because of 
the reduced physiological reserve in this patient group.2–7 
In the UK alone, >50 000 patients aged ≥65 years 
undergo major elective gastrointestinal surgery each 
year.8 One-third of these patients will develop a hospi-
tal-acquired infection, including surgical-site infections, 
body cavity infections and pneumonia. These infections 
cause prolonged hospitalisation, increased healthcare 
costs, reduced short-term and long-term quality of life 
and premature death.6 Around 10% of this patient group 
dies within 6 months of surgery.9
Cardiac output monitoring to guide intravenous fluid 
and inotropic drugs as part of a haemodynamic therapy 
algorithm may reduce postoperative infections by 
improving tissue perfusion and oxygenation, and modi-
fying inflammatory pathways.10–12 There is some evidence 
that this treatment may also reduce the incidence of 
acute kidney injury, another important complication 
which occurs more frequently after major gastrointestinal 
surgery.13
Optimisation of Perioperative Cardiovascular Manage-
ment to Improve Surgical Outcome (OPTIMISE) was the 
largest contemporary trial of this intervention in 734 high-
risk patients undergoing gastrointestinal surgery.9 14 The 
use of a cardiac output-guided haemodynamic therapy 
algorithm did not reduce a composite outcome of 
complications and 30-day mortality compared with usual 
care. However, inclusion in an updated meta-analysis 
indicated that the intervention was associated with a 
reduction in complication rates (intervention, 488/1548 
(31.5%) vs control, 614/1476 (41.6%); RR, 0.77 (95% 
CI 0.71 to 0.83)). The intervention was associated with a 
reduced incidence of postoperative infection (interven-
tion, 182/836 (21.8%) vs control, 201/790 (25.4%); RR, 
0.81 (95% CI 0.69 to 0.95)) and a reduced duration of 
hospital stay (mean reduction, 0.79 days (95% CI 0.62 to 
0.96)). Mortality at longest follow-up showed a non-signif-
icant reduction following the intervention (intervention, 
267/3215 deaths (8.3%) vs control, 327/3160 deaths 
(10.3%); RR 0.86 (95% CI 0.74 to 1.00)). Five partici-
pants in the OPTIMISE intervention group had a serious 
adverse cardiac event within 24 hours of surgery compared 
with none in the control group. However, this was not a 
significant difference, and postoperative troponin levels 
were similar in both trial groups.15
These findings suggest, but do not confirm, that 
perioperative cardiac output-guided haemodynamic 
therapy reduces postoperative infections and other 
complications.16 In the absence of conclusive data, this 
technology has only been partially adopted into routine 
practice because of doubts within the clinical commu-
nity regarding the evidence base.17 18 A definitive trial is 
needed to confirm the effectiveness and cardiac safety of 
this intervention and inform routine clinical practice for 
a large number of patients worldwide.
study hypotheses
We hypothesise that in high-risk patients undergoing 
major elective gastrointestinal surgery cardiac output-
guided fluid therapy combined with low-dose inotrope 
infusion reduces the incidence of postoperative infections 
within 30 days of randomisation compared with usual 
care. Secondary hypotheses are that this intervention 
reduces acute kidney injury within 30 days of randomis-
ation, reduces mortality within 180 days, is cost effective 
and does not lead to an excess of postoperative adverse 
cardiac events.
MEthods And AnAlysEs
The protocol was developed in line with Standard Protocol 
Items for Randomized Trials recommendations.19
study design
Multicentre, international, open, two-arm, parallel group 
randomised controlled trial.
setting
Surgical services of 50 hospitals worldwide. Participant 
recruitment started in January 2017 and is scheduled 
to last 3 years. Recruiting site eligibility criteria include 
having surgical services performing major elective gastro-
intestinal surgery in adults, the ability to provide cardiac 
output monitored haemodynamic therapy and previous 
participation in interventional research.
Participants
Inclusion criteria
Patients aged ≥65 years, with an American Society of Anes-
thesiologists (ASA) physical status classification of II or 
greater, undergoing major elective surgery involving the 
gastrointestinal tract that is expected to take longer than 
90 min.
Exclusion criteria
Patient refusal of informed consent, clinician refusal, 
patients expected to die within 30 days, acute myocardial 
ischaemia or acute pulmonary oedema in the previous 
30 days, any contraindication to low-dose inotropic medi-
cation, pregnancy, previous enrolment in the OPTIMISE 
II trial or current participation in another clinical trial of a 
treatment with a similar biological mechanism or primary 
outcome measure. Patients undergoing procedures 
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involving only the liver, gallbladder or pancreas but 
without resection of bowel are not eligible for inclusion.
Enrolment and randomisation
Strategies for achieving adequate participant enrolment 
will include ensuring the target number of suitable 
recruiting sites is achieved, coordinated trial leadership 
at an international, national and hospital level, local 
engagement of surgeons, anaesthetists and intensivists to 
support screening and trial delivery, and selecting sites 
with experienced local investigators and research teams. 
A full list of OPTIMISE II investigators is included in 
online supplementary file 1. Public and patient input to 
the trial design has informed the trial participant experi-
ence and consent materials to ensure they are acceptable. 
Recruitment targets will be monitored, fed back to sites 
and actively managed throughout the trial.
Potential participants will be screened by research 
staff at the site having been identified from pre-admis-
sion clinic lists, operating theatre lists and by commu-
nication with nursing and medical staff. Before surgery, 
potential participants will be identified and approached 
by a member of the research team. Wherever possible, 
the patient will be approached at least 24 hours prior to 
surgery although due to the nature of the trial inclusion 
criteria, shorter time frames are permitted.
Written informed consent will be obtained from each 
subject prior to participation in this trial. This process 
will include provision of a patient information sheet (see 
online supplementary file 2) accompanied by the rele-
vant consent form (see online supplementary file 3), and 
an explanation of the aims, methods, anticipated bene-
fits and potential harms of the trial. Patients who lack 
capacity to give or withhold informed consent will not be 
recruited. Eligible patients who are not entered into this 
trial will be recorded (including reason not entered).
Randomisation will occur after the participant has 
provided informed consent and shortly before the surgical 
procedure is due to start. Participants will be randomised 
in a 1:1 ratio by minimisation with a random component, 
with group allocation carried out using a central online 
service. Minimisation variables will be country, surgical 
procedure category and ASA class. The surgical proce-
dure categories are resection of colon, rectum or small 
bowel; resection of pancreas and bowel; resection of 
stomach (non-obesity surgery); resection of oesophagus 
(non-obesity surgery); obesity surgery and other surgery 
involving gut resection. The ASA classes are II, III and IV. 
Each participant will be allocated with 80% probability to 
the group that minimises the between group differences 
in these factors among all participants recruited to the 
trial to date, and to the alternative group with 20% proba-
bility. A participant’s treatment group allocation will only 
be revealed once the randomisation is complete.
Perioperative management
The trial intervention period will commence at the start 
of general anaesthesia and continue until 4 hours after 
the completion of surgery (maximum total duration: 
24 hours). Care for all participants has been loosely 
defined to avoid extremes of clinical practice but also 
practice misalignment.20 All participants will receive stan-
dard measures to maintain oxygenation (SpO2≥94%), 
haemoglobin (>8 g/L), core temperature (37°C) and 
heart rate (<100 bpm). A fluid selected by clinicians will 
be administered at 1 mL/kg/hour to satisfy maintenance 
fluid requirements; 5% dextrose is recommended. Addi-
tional fluid will be administered at the discretion of the 
clinician guided by pulse rate, arterial pressure, urine 
output, core-peripheral temperature gradient, serum 
lactate and base excess. For fluid boluses clinicians may 
choose from ‘balanced’ crystalloids, 0.9% sodium chlo-
ride, gelatin-based or starch-based colloids or albumin. 
Mean arterial pressure will be maintained between 60 
and 100 mm Hg using an alpha adrenoceptor agonist or 
vasodilator as required. Postoperative analgesia will be 
provided at the discretion of the clinician in accordance 
with local protocols. This may include epidural infusion 
(bupivicaine and fentanyl), intrathecal opioids (fentanyl, 
morphine, diamorphine), wound catheter infusion 
(bupivacaine), opioid-based patient-controlled analgesia 
system, oral analgesics (including opioids) or intravenous 
infusion (opioids or lidocaine). If required, postoperative 
sedation will be provided with propofol or midazolam.
study interventions
Control group
Participants in the control group will be managed by clin-
ical staff according to usual practice. This will include 
250 mL fluid challenges as above administered at the 
discretion of the clinician guided by pulse rate, arterial 
pressure, urine output, core-peripheral temperature 
gradient, serum lactate and base excess. If a specific 
haemodynamic end point for fluid challenges is to be 
used, the most appropriate would usually be a sustained 
rise in central venous pressure of at least 2 mm Hg for 
20 min or more. Patients should not be randomised if the 
clinician intends to use cardiac output monitoring regard-
less of study group allocation; this is considered ‘clinician 
refusal’ and is a specific exclusion criterion. However, 
clinical staff are free to request cardiac output monitoring 
if this is required to inform the treatment of a participant 
who becomes critically ill (eg, because of severe haemor-
rhage) during the trial intervention period. These events 
will be recorded as protocol deviations.
Intervention group
The intervention will commence from the induction of 
general anaesthesia and continue for 4 hours following 
surgery. Cardiac output, stroke volume and stroke 
volume variation (SVV) will be measured by cardiac 
output monitor. Investigators may only use commer-
cially available cardiac output monitoring equipment 
provided by Edwards Lifesciences (Irvine, California, 
USA) in this trial. The system comprises an EV1000 
monitor and ClearSight (non-invasive) or FloTrac 
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(invasive arterial pressure) sensor. Clinicians will be 
able to choose between the two sensors on a partici-
pant-by-participant basis. No more than 500 mL of intra-
venous fluid will be administered prior to commencing 
cardiac output monitoring. In addition to the main-
tenance, fluid participants will receive 250 mL fluid 
challenges with a recommended solution as required 
in order to achieve a maximal value of stroke volume 
(see figure 1). The absence of fluid responsiveness will 
be defined as the absence of a sustained rise in stroke 
volume of at least 10% for ≥20 min. A low SVV value also 
indicates a low probability of fluid responsiveness21 so 
a fluid bolus should not be given if the SVV is <5%. In 
addition, participants will receive a low-dose inotrope 
infusion at a fixed rate that will be commenced after 
fluid replacement has been initiated. The choice of 
inotrope will be made at the discretion of the local inves-
tigator, according to local preference and availability. 
Figure 1 Algorithm for cardiac output-guided haemodynamic therapy for participants in the Optimisation of Perioperative 
Cardiovascular Management to Improve Surgical Outcome II intervention group.
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The options are dobutamine at a dose/rate of 2.5 µg/
kg/min and dopexamine at an equipotent dose/rate 
of 0.5 µg/kg/min. The infusion rate will be reduced 
and/or discontinued if the participant develops a 
tachycardia (heart rate >100 bpm) for >30 min despite 
adequate anaesthesia and analgesia. Data collection 
and follow-up for such participants will be performed as 
normal. All other management decisions will be taken 
by clinical staff.
blinding and procedures to minimise bias
OPTIMISE II is a pragmatic trial of a treatment algorithm. 
It is not possible to conceal treatment allocation from 
all staff in trials of this type. Therefore, this trial will be 
open-label, and participants and the staff delivering the 
intervention will be unblinded. However, procedures will 
be put in place to minimise the possibility of bias arising 
because research staff become aware of treatment group 
allocation. Those assessing clinical outcomes (research 
associates and principal investigators (PIs)) should not be 
involved in the participant’s care and should be unaware 
of treatment group allocation. Those contacting the 
participant during follow-up (eg, at day 30) should also 
be unaware of treatment group allocation. The research 
associate undertaking the participant follow-up will make 
a self-assessment of their degree of blinding after the visit.
The randomisation method used is not predictable 
so there is little risk of selection bias for research staff 
enrolling patients.22 The trial management group and the 
trial steering committee will not see results broken down 
by treatment arm during the trial. Final analysis will occur 
once all follow-up data are collected, the final statistical 
analysis plan has been signed off and data cleaning has 
occurred. The independent data monitoring committee 
will see outcome results by treatment group but data will 
be handled by an independent statistician, not otherwise 
involved in the trial.
data collection
Postoperative outcomes will be recorded by research staff 
that are unaware of study group allocation as detailed 
below and entered onto paper case report forms before 
entry onto the secure web-based data entry platform. A 
full list of data collected from all participants is included 
in online supplementary file 1. Data will be collected 
from all participants randomised regardless of whether 
the participant received the intervention according to 
the trial protocol or not. The occurrence of a specified 
clinical outcome will be confirmed by the local PI, or an 
appropriately qualified delegate if the PI is aware of the 
participant group allocation.
data monitoring
The sponsor will have oversight of trial conduct at sites, 
with the Trial Management Group having day-to-day 
responsibility for quality control and quality assurance 
of the data collected. An independent Data Monitoring 
and Ethics Committee (DMEC) and a Trial Steering 
Committee (TSC) have been appointed and function 
in accordance with an agreed charter. DMEC and TSC 
reviews will be held six monthly, or less frequently if 
deemed appropriate by the respective committees. No 
formal interim analysis for efficacy is planned. However, 
the DMEC will monitor the safety and efficacy of the 
interventions during the period of recruitment into the 
trial. The DMEC will review patient recruitment, data 
quality, protocol compliance and loss to follow-up. The 
DMEC will make recommendations to the TSC who will 
make final decisions on trial continuation.
trial outcomes
Primary end point
The primary end point of the trial is postoperative infec-
tion rate within 30 days of randomisation. This is defined 
as one or more of the following infections of Clavien-
Dindo grade II or greater: superficial surgical site infec-
tion, deep surgical-site infection, organ space surgical-site 
infection, pneumonia, urinary tract infection, laborato-
ry-confirmed blood stream infection or infection, source 
uncertain; this is defined as an infection which could be 
more than one of the above but it is unclear which.
Secondary end points
1. Mortality within 180 days of randomisation.
2. Acute kidney injury of Clavien-Dindo grade II or great-
er within 30 days from randomisation.
3. Acute cardiac event of Clavien-Dindo grade II or great-
er within 24 hours of randomisation. This is defined 
as one or more of arrhythmia, myocardial infarction, 
myocardial injury after non-cardiac surgery, cardiac 
arrest with successful resuscitation or cardiogenic pul-
monary oedema.
4. Acute cardiac event of Clavien-Dindo grade II or great-
er within 30 days of randomisation.
Planned process measures
1. Duration of hospital stay (number of days from rando-
misation until hospital discharge).
2. Number of critical care free days, up to 30 days from 
randomisation. A critical care free day is defined as a 
day in which the participant is alive and is not in a level 
2 or level 3 critical care bed.
Health economic outcomes
1. Healthcare costs during 180 days from randomisation 
from the perspective of UK health services.
2. Quality-adjusted life-years (QALYs) during 180 days 
from randomisation.
3. Incremental cost-effectiveness ratio.
Assessment of outcomes
The primary outcome will be assessed using informa-
tion from a participant’s medical records. Participants 
discharged from hospital before day 30 will be contacted 
shortly after day 30 to ascertain whether they have received 
any new treatment since discharge, or if they have been 
readmitted to hospital or seen a doctor since discharge. 
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For participants who have received further treatment or 
seen a health professional since discharge, further details 
will be collected directly from the hospital/doctor or 
from the participant’s health records.
Mortality will be established by a participant medical 
record review or data from national databases. 
Morbidity outcomes will be assessed by a review of 
the participant’s medical records, and by telephone 
interview in the same way as the primary outcome for 
30-day outcomes. Length of stay in hospital and crit-
ical care will be assessed by a review of the participant’s 
medical records. Secondary care resource use will be 
assessed using electronic health records obtained from 
NHS Digital for participants in UK sites. Participants’ 
health-related quality of life will be assessed (UK sites 
only)—using the EuroQol 5-dimension, 3-level (EQ5D-
3L) questionnaire, administered in person at trial 
enrolment and then by telephone interview at 30 and 
180 days post randomisation.
baseline and other follow-up data
Data on baseline demographic and clinical partici-
pant characteristics, perioperative events, details of the 
trial intervention and all other forms of postoperative 
morbidity will be collected by a review of the participant’s 
medical records (see online supplementary file 1).
The schedule of enrolment, interventions and assess-
ments is summarised in table 1.
Protocol compliance monitoring
Predefined protocol deviations that will be reported 
include failure to use cardiac output monitoring in an 
intervention group participant, failure to administer 
inotrope to an intervention group participant, admin-
istration of the incorrect dose of inotrope to an inter-
vention group participant or the use of cardiac output 
monitoring in a control group participant. Protocol devi-
ations will be monitored and feedback given to centres 
with high levels of non-compliance.
sample size
In order to detect a 5% absolute reduction (from 30% 
to 25%) for the primary outcome of postoperative infec-
tion up to 30 days (a risk ratio of 0.83), with 80% power 
and an overall type I error rate of 5%, we require 2502 
participants (1251 per arm). This sample size would also 
Table 1 Schedule of enrolment, interventions and assessments for participants in the Optimisation of Perioperative 
Cardiovascular Management to Improve Surgical Outcome II trial
Timepoint
Enrolment Allocation Post-randomisation
Before 
surgery 0
Intra-
operative
4 hours post 
surgery 24 hours 30 days 180 days
Enrolment
Eligibility screen X
Informed consent X
Allocation X
Interventions
Cardiac output-guided 
haemodynamic therapy
Usual care
Assessments
Demographic 
information
X
Medical history X
EuroQol 5-dimension, 
3-level (UK only)
X X X
Intraoperative 
information
X X
Fluids and inotropic 
therapy
X X
Acute cardiac event X X
Postoperative infection X
Acute kidney injury X
Other postoperative 
morbidity
X
Mortality X
End-of-trial form X
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allow us to detect an absolute reduction in the primary 
outcome of 6% (from 30% to 24%) with 92% power.
statistical analysis
Analyses will be performed according to intention-to-
treat; all participants with a recorded outcome will be 
included in the analysis, and analysed according to the 
treatment to which they were randomised.23 Summary 
statistics by group, treatment effects, 95% CIs and p values 
will be presented for primary and secondary outcomes, 
and process measures. Baseline and all other follow-up 
data for the two groups will be summarised by treatment 
group, but not subjected to statistical testing.
The primary outcome of postoperative infection 
within 30 days from randomisation will be analysed 
using a mixed-effects logistic regression model with a 
random intercept for country.24 The model will adjust 
for surgical procedure category, age, gender, ASA class, 
baseline haemoglobin and baseline creatinine. ASA class 
and procedure category will be included as categorical 
variables. The categories for ASA class are II, III and IV. 
The categories for procedure are (1) resection of colon, 
rectum or small bowel; (2) resection of pancreas and 
bowel; (3) resection of stomach (non-obesity surgery); 
(4) resection of oesophagus (non-obesity surgery); (5) 
obesity surgery; and (6) other surgery involving gut resec-
tion. Age, baseline haemoglobin and baseline creatinine 
will be adjusted for using restricted cubic splines with 
three knots, and knot locations based on Harell’s recom-
mendations.25 26 Missing baseline data will be accounted 
for using mean imputation.27P values <0.05 will be consid-
ered statistically significant. A statistical analysis plan 
will be signed off prior to (1) data analysis taking place 
and (2) any member of the trial team having access to 
unblinded data.
subgroup analysis
A subgroup analysis will be performed for the primary 
outcome (postoperative infection within 30 days of rando-
misation) to assess whether the effect of the intervention 
differs by planned surgical procedure category. Planned 
surgical procedure category has six categories: (1) resec-
tion of colon, rectum or small bowel; (2) resection of 
pancreas and bowel; (3) resection of stomach (non-obe-
sity surgery); (4) resection of oesophagus (non-obe-
sity surgery); (5) obesity surgery and (6) other surgery 
involving gut resection.
health economic analysis
A cost–utility analysis will evaluate the cost-effectiveness 
of cardiac output-guided fluid therapy with low-dose 
inotrope infusion compared with current usual practice 
from the perspective of the UK health services. Costs and 
outcomes will be evaluated over 180 days of follow-up from 
randomisation. The analysis will include the cost of inter-
vention and the cost of hospital care incurred by patients 
during this 180-day period. The resources incurred for 
cardiac output monitoring in the intervention arm will be 
obtained from trial centres. Data on hospital admissions 
will be recorded on the Case Report Form. For UK partic-
ipants, secondary care electronic health records over the 
trial duration period will be obtained from NHS Digital 
Hospital Episode Statistics.28 Data on hospital admissions, 
critical care and outpatient visits will be combined with 
published unit costs to estimate the respective hospital 
care costs.29
Outcomes in the health economic analysis will be 
measured in terms of QALY estimated using the EQ-5D-3L 
questionnaire data, collected at baseline, 30 and 180 days 
for UK participants, and UK population utility weights.30 
Appropriate statistical techniques will be applied to eval-
uate cost-effectiveness of cardiac output-guided fluid 
therapy with low-dose inotrope infusion using the trial-
wide data and the more detailed further data collected 
for UK participants. The analysis will gauge the additional 
cost per QALY gained in the intervention arm compared 
with usual care using an incremental cost-effective-
ness ratio (ICER). Non-parametric bootstrapping with 
replacement using 5000 iterations based on the observed 
data will be carried out to estimate the 95% CI for the 
ICER and summarise the probability of the intervention 
to be cost-effectiveness across a range of cost-effectiveness 
thresholds.31
safety monitoring
All interventions within the OPTIMISE II trial are 
already in routine clinical use for patients undergoing 
major gastrointestinal surgery. The safety of the inter-
vention will be monitored by recording acute cardiac 
events at 24 hours and 30 days after randomisation as a 
trial outcome. These events will be monitored at inter-
vals by the DMEC and will not be recorded separately as 
an adverse event. Serious adverse events (SAEs) will be 
reported to the trial sponsor within 72 hours of research 
sites becoming aware of them. An SAE is defined as an 
adverse event resulting in death, threat to life, hospital-
isation (or prolongation of hospitalisation) or persistent 
disability/incapacity which is judged to be related to the 
use of study procedures, and not an expected occurrence 
after abdominal surgery.
Monitoring/auditing
The trial will be audited annually by the sponsor trials 
unit. In addition, each recruiting site will have two on-site 
monitoring visits during the trial recruitment period. If 
required, additional monitoring visits may be organised 
to address specific trial related problems at a site. Full 
source data verification will be carried out for the primary 
outcome at 30-day follow-up for up to 10 patients at each 
site visit.
Patient and public involvement
The OPTIMISE II trial was reviewed in detail by the Royal 
College of Anaesthetists Patient, Carer and Public Involve-
ment and Engagement (PCPIE) in Research Group which 
was formed to provide high-quality guidance on research 
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proposals in the field of perioperative medicine. Detailed 
feedback from this group has informed both the design 
and conduct of the trial. The group agreed that the find-
ings of the previous smaller trial (OPTIMISE) were not 
conclusive and required confirmation. Importantly, the 
recently completed James Lind Alliance Priority Setting 
Partnership for Anaesthesia and Perioperative Care has 
ranked this topic among the 10 most important research 
questions in our field. This confirms the importance of 
this research question to both patients and clinicians. 
The RCoA PCPIE group nominated a member to join the 
OPTIMISE II project group as a lay representative. This 
member has been involved throughout the preparation 
of the trial, providing detailed input and representing the 
views of the PCPIE group with respect to issues of safety 
and the experience of participating patients. The Trial 
Steering Committee includes a lay member, providing 
independent non-medical input to trial conduct. A lay 
summary of the trial results will be made available to 
participants.
Ethics and dissemination
The OPTIMISE II trial has been approved by the UK 
National Research Ethics Service and has been approved 
by responsible ethics committees in all participating 
countries. All participating centres have full ethical 
approval. Any additional recruiting sites joining the trial 
will require full ethical approval prior to participation. 
Data arising from this research will be made available 
to the scientific community in a timely and responsible 
manner. A detailed scientific report will be submitted 
to a widely accessible scientific journal on behalf of the 
OPTIMISE II Trial Group. Further dissemination will 
include presentations at international scientific meet-
ings, public presentations, webcasts and reports targeting 
international healthcare policymakers, professional 
organisations, front-line healthcare workers, patients 
and the public. Deidentified data will also be shared with 
other authenticated researchers for further research and 
research publications on this topic, but only if they guar-
antee to preserve the confidentiality of the information 
requested. Requests for data sharing will be considered by 
the data sharing committee of the supporting trials unit 
(Pragmatic Clinical Trials Unit, Queen Mary University 
of London) in accordance with their data sharing policy.
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